JP2004521950A5 - - Google Patents

Download PDF

Info

Publication number
JP2004521950A5
JP2004521950A5 JP2003511816A JP2003511816A JP2004521950A5 JP 2004521950 A5 JP2004521950 A5 JP 2004521950A5 JP 2003511816 A JP2003511816 A JP 2003511816A JP 2003511816 A JP2003511816 A JP 2003511816A JP 2004521950 A5 JP2004521950 A5 JP 2004521950A5
Authority
JP
Japan
Prior art keywords
aerosol formulation
appetite
loss
mammal
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003511816A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004521950A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2002/003161 external-priority patent/WO2003006010A1/en
Publication of JP2004521950A publication Critical patent/JP2004521950A/ja
Publication of JP2004521950A5 publication Critical patent/JP2004521950A5/ja
Pending legal-status Critical Current

Links

JP2003511816A 2001-07-10 2002-07-10 Δ8テトラヒドロカンナビノールのエアロゾル製剤 Pending JP2004521950A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30502101P 2001-07-10 2001-07-10
PCT/GB2002/003161 WO2003006010A1 (en) 2001-07-10 2002-07-10 Aerosol formulations of δ8 tetrahydrocannabinol

Publications (2)

Publication Number Publication Date
JP2004521950A JP2004521950A (ja) 2004-07-22
JP2004521950A5 true JP2004521950A5 (enExample) 2006-01-05

Family

ID=23178964

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003511816A Pending JP2004521950A (ja) 2001-07-10 2002-07-10 Δ8テトラヒドロカンナビノールのエアロゾル製剤

Country Status (7)

Country Link
US (1) US20050079136A1 (enExample)
EP (1) EP1404314A1 (enExample)
JP (1) JP2004521950A (enExample)
KR (1) KR20040032851A (enExample)
AU (1) AU2002319422C1 (enExample)
CA (1) CA2453389A1 (enExample)
WO (1) WO2003006010A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4467883B2 (ja) * 2001-02-14 2010-05-26 ジーダブリュー・ファーマ・リミテッド 医薬製剤
US20040248970A1 (en) * 2003-04-10 2004-12-09 Webster G.R. Barrie CBD-delta8-THC composition
WO2006091922A1 (en) * 2005-02-25 2006-08-31 Unimed Pharmaceuticals, Inc. Dronabinol compositions and methods of using same
US20070060639A1 (en) * 2005-09-09 2007-03-15 University Of Kentucky Compositions and methods for intranasal delivery of tricyclic cannabinoids
US8039509B2 (en) 2006-11-10 2011-10-18 Johnson Matthey Public Limited Company Composition comprising (−)-Δ9-trans-tetrahydrocannabinol
US8980940B2 (en) 2006-11-10 2015-03-17 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
DE102007063210A1 (de) * 2007-12-20 2009-06-25 Eberhard-Karls-Universität Tübingen Universitätsklinikum Arzneimittel zur Behandlung von Phantomphänomenen
US11253472B2 (en) 2012-10-04 2022-02-22 Benuvia Therapeutics Llc Oral cannabinoid formulations
US9345771B2 (en) 2012-10-04 2016-05-24 Insys Development Company, Inc. Oral cannabinoid formulations
US10265293B2 (en) 2012-10-04 2019-04-23 Insys Development Company, Inc. Oral cannabinoid formulations
WO2015048508A1 (en) 2013-09-26 2015-04-02 Sekura Ronald D Topical treatments incorporating cannabis sp. derived botanical drug product
WO2015195711A2 (en) * 2014-06-16 2015-12-23 Shurtleff, James, Kevin Method and devices for manufacturing and delivering of aerosolized formulations
CA3111682A1 (en) 2014-06-26 2015-12-30 Island Breeze Systems Ca, Llc Mdi related products and methods of use
US11793769B2 (en) 2014-08-25 2023-10-24 Jai Shankar Sukul Device with compositions for delivery to the lungs, the oral mucosa and the brain
US9717683B1 (en) 2016-06-29 2017-08-01 Ep Pharma, Llc Low-temperature inhalation administration of cannabinoid entities
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
US10231948B2 (en) 2017-02-27 2019-03-19 Jason Ty Nguyen Metered dose inhaler compositions, systems, and methods
US11202771B2 (en) 2018-01-31 2021-12-21 Treehouse Biotech, Inc. Hemp powder
EP3864000A4 (en) 2018-10-10 2022-08-10 Treehouse Biosciences, Inc. CANNABIGEROL SYNTHESIS
US12496271B2 (en) 2019-02-22 2025-12-16 Benuvia Operations, Llc Oral cannabinoid formulations
US20200352191A1 (en) * 2019-05-06 2020-11-12 Karl Lonsbery Edible formulations and uses thereof
US11806645B1 (en) 2019-05-07 2023-11-07 Cannaceutical Extractions LLC Methods of producing CBD/THC oils
WO2021071967A1 (en) * 2019-10-09 2021-04-15 Island Breeze Systems Ca, Llc Compositions for pulmonary delivery of cannabinoids and associated methods and systems
US20230131989A1 (en) * 2020-07-29 2023-04-27 Medterra Pharma Llc Cannabinoid compositions and methods of using for the treatment of non-eosinophilic inflammation and inflammatory disorders
US20220387352A1 (en) * 2020-07-29 2022-12-08 Medterra Pharma Llc Cannabinoid compositions and methods of using for the treatment of non-eosinophilic inflammation and inflammatory disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803978A (en) * 1985-08-09 1989-02-14 Johnson Iv John J Apparatus for actuating an inhaler
IL99468A (en) * 1991-09-12 1997-09-30 Yissum Res Dev Co (3s, 4s)-delta- 6-tetrahydrocannabinol- 7-oic acids and derivatives thereof, processes for their preparation and pharmaceutical compositions containing them
IL102082A (en) * 1992-06-02 1997-07-13 Yissum Res Dev Co Antiemetic composition containing a cannabinol derivative
GB9726916D0 (en) * 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
US6509005B1 (en) * 1998-10-27 2003-01-21 Virginia Commonwealth University Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler
CA2341035A1 (en) * 1999-07-08 2001-01-18 Orlando Hung Pulmonary delivery of liposomal-encapsulated cannabinoids

Similar Documents

Publication Publication Date Title
JP2004521950A5 (enExample)
ES2745064T3 (es) Formulación superfina de formoterol
JP2005539046A (ja) 特異的な抗コリン作用薬、β−2アゴニスト、および副腎皮質ステロイドを含む、治療薬および組成物
US20040235807A1 (en) Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea
HRP20130835T1 (hr) Farmaceutske formulacije otopine za davanje kao stlaäśeni inhalat u inhalatoru
JP2004521950A (ja) Δ8テトラヒドロカンナビノールのエアロゾル製剤
AU2002319422A1 (en) Aerosol formulations of delta8 tetrahydrocannabinol
WO2011136754A1 (en) A medicament developed for the treatment of respiratory diseases
Woodcock et al. Modulite® technology: pharmacodynamic and pharmacokinetic implications
WO2011136753A1 (en) Combination of carmoterol and fluticasone for use in the treatment respiratory diseases
US20100136121A1 (en) Medicaments
Everard et al. In vitro assessment of drug delivery through an endotracheal tube using a dry powder inhaler delivery system.
Zainudin Therapeutic Aerosol Principles and Practices
Shah AEROSOL BRONCHODILATORS-PRACTICAL CONSIDERATIONS